Dipartimento di Scienze Farmaceutiche, Università di Pisa, Via Bonanno 6, 56100 Pisa, Italy.
Mol Pharm. 2010 Oct 4;7(5):1871-6. doi: 10.1021/mp1001137. Epub 2010 Jul 27.
Several nimesulide preparations (i.e., tablet form, gels) have been marketed, but no parenteral solution has achieved the market because of their low wettability and unsatisfactory chemical-physical properties required for parenteral use. In this paper we describe the synthesis of the nimesulide prodrug 1 and its anti-inflammatory and antihyperalgesic properties. Pharmacological studies, carried out to evaluate the in vivo anti-inflammatory and analgesic activities of compound 1 and nimesulide, showed that sodium sulfamate 1 is an effective nimesulide prodrug that can be administered by parenteral route, undergoing a satisfactory absorption and an extensive transformation into the active nimesulide compound. Moreover, the evaluation of the plasma concentrations of nimesulide after rat treatment with compound 1 showed an increased and dose-dependent release of nimesulide. In contrast, the plasma concentrations of nimesulide, after "native" drug administration, still remain substantially unchanged. These preliminary results prompt further investigations on this prodrug as a possible candidate for parenteral use.
已有几种尼美舒利制剂(例如片剂、凝胶)上市,但由于其润湿性低和不满足注射用所需的理化性质,尚无注射用制剂获得市场批准。本文描述了尼美舒利前药 1 的合成及其抗炎和抗痛觉过敏特性。为评估化合物 1 和尼美舒利的体内抗炎和镇痛活性而进行的药理学研究表明,磺胺酸钠 1 是一种有效的尼美舒利前药,可通过注射途径给药,具有良好的吸收和广泛转化为活性尼美舒利化合物。此外,大鼠给予化合物 1 后检测尼美舒利的血浆浓度表明尼美舒利的释放呈增加的剂量依赖性。相比之下,给予“天然”药物后,尼美舒利的血浆浓度仍基本不变。这些初步结果促使对该前药进行进一步研究,作为注射用的候选药物。